Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Logan Lutton is a contributing author for 

Articles

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.

Acne Treatment Insights From SDPA Fall

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

A clinical trial and laboratory study assessed skin’s hydration, antioxidation, and wrinkle presence after treatment with cacao.

Cacao Powder Shows Promise in Rejuvenating Aging Skin

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Conferences and Meetings Calendar 2024: December

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Beyond the Stigma: Patient Stories in Vitiligo Management

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Videos

various aspects of vitiligo management through case-based discussions and insights including navigating emotional and clinical challenges to balancing treatment options with coverage constraints.

Ted Lain, MD, MBA, FAAD offers insights into navigating the emotional and clinical challenges in vitiligo management. 

Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses balancing vitiligo treatments with coverage challenges.

Balancing Vitiligo Treatments with Coverage Challenges

Ted Lain, MD, MBA, FAAD discusses a case which addresses location-specific concerns and treatment challenges in vitiligo management. 

Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo. 

Case Based Peer Perspectives

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

EP: 1.Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

EP: 2.Balancing Vitiligo Treatments with Coverage Challenges

EP: 3.Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP: 4.Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib